摘要
金属配合物抗肿瘤研究,尤其是铂类药物,已取得了相对令人瞩目的成功,但同时也面临着包括耐药性和毒副作用等诸多问题。近年来钌配合物作为新的抗癌药物引起了人们的注意。在非铂系药物中,金属钌配合物是最有前途的抗癌药物之一,国际上普遍认为钌和钌的配合物属于低毒性,容易吸收并在体内很快排泄。本文将着重介绍钌配合物与DNA结合后进一步引发的细胞内核酶活性抑制研究,从新的角度来诠释钌配合物的抗肿瘤研究最新进展。
The anti-tumor study of metal complexes, especially the platinum-base drugs, has achieved remarkable success but still facing several problems such as drugs resistance and side effects. Recently, ruthenium complexes attract many scientists＇ interests with their brand new application of anti-tumor drugs. In the series of non- platinum drugs, ruthenium complexes are regarded as one of the most potential anti-tumor drugs for the reason not merely the metal ruthenium and its complexes exhibit low toxicity but also they can be efficiently absorbed and excreted for human body. Herein, the study of the follow-up inhibition towards nucleus enzymes induced by the binding between ruthenium complexes and DNA was expatiated, introducing the advance anti-tumor applications of ruthenium complexes in new perspectives.
出处
《无机化学学报》
SCIE
CAS
CSCD
北大核心
2015年第9期1667-1677,共11页
Chinese Journal of Inorganic Chemistry
基金
973项目(No.2015CB85630)
国家自然科学基金(No.21172273
21171177
21471164)
教育部高校博士点基金博导类课题(No.20110171110013)资助项目
